Table 1.
Demographics and clinical characteristics of patients with PsA initiating tofacitinib, stratified by post-index tofacitinib treatment regimen
| Patients with PsA initiating tofacitinib (N = 318) | ||
|---|---|---|
| Tofacitinib monotherapy (n = 199) | Tofacitinib combination therapy (n = 119) | |
| Age, yearsa | ||
| Mean (SD) | 51.8 (11.4) | 52.5 (10.0) |
| Median (IQR) | 52 (46–59) | 54 (47–59) |
| Sex, n (%) | ||
| Female | 138 (69.3) | 80 (67.2) |
| Male | 61 (30.7) | 39 (32.8) |
| US region, n (%)a | ||
| Midwest | 31 (15.6) | 18 (15.1) |
| Northeast | 51 (25.6) | 30 (25.2) |
| South | 65 (32.7) | 41 (34.5) |
| West | 25 (12.6) | 10 (8.4) |
| Unknown | 27 (13.6) | 20 (16.8) |
| Payer, n (%)b | ||
| Commercial | 175 (87.9) | 107 (89.9) |
| Medicare | 24 (12.1) | 12 (10.1) |
| PsA disease duration daysc | ||
| Mean (SD) | 760.5 (318.8) | 748.3 (319.7) |
| Median (IQR) | 818 (493.5–1036.5) | 827 (489.0–985.5) |
IQR interquartile range, N number of patients in each cohort, n number of patients in each category, PsA psoriatic arthritis, SD standard deviation, US United States
aRecorded on the index date
bFirst payer over the index date
cDays between PsA diagnosis and index date, excluding the end date